Építés alatt – nem éles oldal
Belépés
Visszavonva3. fázis

A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight

A legfontosabb adatok

Ki végzi
Eurofarma Laboratorios S.A.
Hol
Brazília2 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Visszavonva
Fázis
3. fázis
Kezdés
2026. ápr.
Várható befejezés
2028. márc.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg
  • ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg
  • SIB Group Sibus (Sibutramine) 15mg
  • Placebo Group
A regiszteradat frissítve
2025. december 18.
Miért állt le
Strategic change in development priorities

Ki vehet részt

Életkor
18 év – 60 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 29 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female volunteers aged between 18 and 60 years (inclusive)
  • BMI ≥ 27kg/m2 and < 45kg/m2. Patients with a BMI ≥ 27kg/m2 and < 30kg/m2 must have at least one of the following comorbidities to be included in the study: dyslipidemia, systemic arterial hypertension (SAH), pre-diabetes (fasting glucose ≥ 100mg/dL and < 126 mg/dL and/or HbA1c ≥ 5.7% and < 6.5%] and/or sleep apnea (confirmed by polysomnography performed up to three months before enrollment in the study)
  • Women of childbearing age must use adequate contraceptive methods
  • Volunteers willing and able to comply with all aspects of the protocol
  • Signing the Informed Consent Form (ICF) before performing any study procedure

Ki nem vehet részt

  • Participation in a lifestyle change program within the three months prior to the start of the study
  • Treatment with drugs (prescription or over-the-counter) or alternative drugs intended to promote weight loss within the three months prior to the start of the study. These medications include, among others: liraglutide, orlistat, sibutramine, topiramate, naltrexone, bupropion, sertraline, fluoxetine, duloxetine. Note: The use of metformin or other hypoglycemic drugs prescribed for the treatment of polycystic ovary syndrome or prevention of diabetes is not permitted
  • Treatment with drugs known to cause significant weight gain within three months of starting the study. These medications include, among others: corticosteroids, tricyclic antidepressants, atypical antipsychotics, and mood stabilizers (such as imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, lithium)
  • History of psychiatric disorder requiring previous drug treatment
  • Hypersensitivity to sibutramine, topiramate, or to any component of the investigational product formulation
  • Known hypersensitivity to any component of the investigational drug formulation
  • Presence of diabetes mellitus
  • History of coronary artery disease (angina, history of myocardial infarction)
  • Congestive heart failure
  • History of tachycardia
  • History of peripheral obstructive arterial disease
  • History of arrhythmia
  • History of cerebrovascular disease (stroke or transient ischemic attack)
  • Inadequately controlled systemic arterial hypertension (> 145/90 mmHg)
  • History or active pulmonary arterial hypertension
  • History or presence of eating disorders such as bulimia and anorexia
  • Hepatic failure Child-Pugh categories B or C (Child-Pugh scale score ≥ 7 points)
  • Current use of monoamine oxidase inhibitors (MAOIs) or any other drug treatment for psychiatric disorders
  • Unstable thyroid disease or replacement therapy
  • Moderate or severe renal impairment (estimated creatinine clearance < 70 mL/min)
  • Any medical or other condition that, in the opinion of the investigator(s), prevents the participant from participating in the clinical trial, such as significantly abnormal laboratory results or any physical or mental condition that prevents compliance with the protocol
  • Glaucoma or high intraocular pressure
  • Urinary lithiasis
  • Pregnancy or lactation

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

A phase 3, multicenter, randomized, double-blind, double-dummy, parallel-group, active-drug- and placebo-controlled clinical trial to assess the safety, efficacy and superiority of the new fixed-dose combination sibutramine IR/topyramat XR in weight reduction in overweight adults with comorbidity(ies) or obesity

A vizsgálat 4 csoportja

  • Experimental drug (Sibutramine IR 15mg / Topiramate XR 75mg)A vizsgált kezelés

    ADF1 Group Eurofarma drug association of sibutramine IR 15mg / topiramate XR 75mg

    Kezelés: ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg

  • Experimental drug (Sibutramine IR 15mg / Topiramate XR 100mg)A vizsgált kezelés

    ADF2 Group Eurofarma drug association of sibutramine IR 15mg (Sibus®) Topiramate XR 100mg from Eurofarma Laboratórios S.A..

    Kezelés: ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg

  • Sibus (Sibutramine 15mg)Már használt kezelés, összehasonlításként

    SIB Group Sibutramine 15mg

    Kezelés: SIB Group Sibus (Sibutramine) 15mg

  • Placebo GroupPlacebo, összehasonlításként

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 3, Randomized, Double-blind, Double-dummy, Parallel-group, Active Drug and Placebo-controlled, Safety, Efficacy and Superiority of Sibutramine IR/Topiramate XR in Overweight Adults With Comorbidities/Obesity
A regiszteradat frissítve
2025. december 18.